Cargando…
Sustainable rare diseases business and drug access: no time for misconceptions
Legislative incentives enacted in Europe through the Regulation (EC) No. 141/2000 to incentivize orphan drug development have over the last 12 years constituted a powerful impetus toward R&D directed at the rare diseases population. However, despite therapeutic promises contained in these projec...
Autores principales: | Rollet, Pierrick, Lemoine, Adrien, Dunoyer, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735431/ https://www.ncbi.nlm.nih.gov/pubmed/23879976 http://dx.doi.org/10.1186/1750-1172-8-109 |
Ejemplares similares
-
Value and specificity of rare diseases business model-is the pursuit of this societal priority sustainable?
por: Dunoyer, M, et al.
Publicado: (2012) -
Errors and Misconceptions in Drug Prescribing
por: Beeley, Linda
Publicado: (1980) -
Six Persistent Research Misconceptions
por: Rothman, Kenneth J.
Publicado: (2014) -
Gastroparesis: Myths, Misconceptions, and Management
por: Cangemi, David J, et al.
Publicado: (2023) -
Chronic Lyme disease: misconceptions and challenges for patient management
por: Halperin, John J
Publicado: (2015)